The biotechnology services market size has grown strongly in recent years. It will grow from $126.58 billion in 2023 to $133.74 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The historical growth in biotechnology services can be attributed to robust economic growth in emerging markets, heightened collaborations with other research institutes and companies, and an increased demand for food.
The biotechnology services market size is expected to see strong growth in the next few years. It will grow to $163.12 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Forecasted growth in biotechnology services is fueled by technological advancements, increased demand for agriculture-based services, and the rise of synthetic biology. Key trends include strategic collaborations, cloud-based data management, advanced sequencing and AI in drug research, digitalization in clinical trials, automation in diagnostics, and investments in synthetic biology for solutions in medicine, food supplies, chemicals, and renewable energy.
The increasing prevalence of diseases such as hepatitis B, diabetes, and cancer is fueling extensive research within the realm of biotechnology. This interdisciplinary field utilizes tools from biology and chemistry to scrutinize the genetic material of bacteria and viruses, effectively combating disease-causing agents. Notably, oncology research remains a cornerstone for biopharmaceutical companies, with advancements in stem cell therapy, monoclonal antibody treatments, and genome sequencing paving the way for significant medical applications. As per the Indian Economic Survey 2021, the Indian biotechnology sector is anticipated to burgeon to a valuation of US$ 150 billion by 2025. Consequently, the surge in disease prevalence and substantial investments in research and development are expected to be instrumental in propelling the growth of the biotechnology services market.
The escalating demand for clinical solutions catering to chronic disease treatments is set to be a significant driver for the expansion of the biotechnology services market. Chronic diseases encompass enduring medical conditions persisting for an extended duration, typically three months or more. Biotechnology services play a pivotal role in offering innovative clinical solutions for managing chronic diseases, including advanced therapies, precision medicine, and targeted treatments personalized to individual patients. These advancements significantly enhance the management and outcomes of chronic ailments. For instance, as per the World Health Organization (WHO) in September 2022, chronic diseases account for 74% of global deaths, amounting to 41 million fatalities annually. This includes 17.9 million deaths attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2.0 million to diabetes. Hence, the mounting demand for clinical solutions tailored to chronic disease treatment is a driving force behind the growth of the biotechnology services market.
Collaborations and partnerships between industry players are becoming increasingly prevalent in the biotech services sector. In January 2021, Novartis, a Swiss pharmaceutical company, entered into a collaboration with Alnylam, a US-based biopharmaceutical company. This partnership aimed to explore Alnylam's siRNA technology and develop targeted therapies to restore liver function. Under an exclusive three-year research collaboration, Alnylam would leverage Novartis' target-specific assays to develop and test potential siRNAs. Once a lead candidate is identified, Novartis would spearhead further development and clinical research efforts.
Key companies within the biotechnology services market are dedicated to pioneering innovative therapies, such as biomarker algorithms for the primary treatment of patients with non-small cell lung cancer (NSCLC). Biomarker algorithms encompass mathematical or computational models integrating data from multiple biological indicators to provide comprehensive assessments of specific medical conditions. For instance, in April 2023, Strata Oncology Inc., a US-based precision oncology company, introduced Strata Select - a groundbreaking molecular profiling test for advanced cancer patients. Noteworthy for being the first immunotherapy biomarker algorithm covered by Medicare across solid tumors, Strata Select empowers oncologists to make more informed treatment decisions, thereby enhancing patient outcomes.
In October 2021, Amgen, a US-based biopharmaceutical company, completed the acquisition of Teneobio for $2.5 billion. The acquisition included Teneobio's bispecific and multispecific antibody technologies, enhancing Amgen's antibody expertise and BiTE platform. This strategic move aims to advance the discovery of novel molecules for treating various diseases within Amgen's key therapeutic areas. TeneoBio, the acquired company, is a US-based biotechnology firm known for its expertise in producing human heavy chain antibodies.
Major companies operating in the biotechnology services market report are Parexel International Corporation, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, IQVIA, ICON PLC, Charles River Laboratories, Syneos Health, Sartorius AG, Precision for Medicine Inc., Novartis, Eppendorf Asia Pacific Sdn. Bhd., Emmessar Biotech & Nutrition Ltd., Vcanbio Cell & Gene Engineering Corp., Ltd., Ke Rui Gene, Absea Biotechnology Ltd., CStone Pharm-B, Daiichi Sankyo, bitBiome, Taisho Pharmaceutical, AGC Biologics, Hamamatsu Pharma Research, Artios Pharma, AstraZeneca, Bio Products Laboratory (BPL), Cambridge Bioscience, Shire Pharmaceuticals Ltd., BTG Ltd., eXmoor Pharma, 4D Pharma PLC, Touchlight Genetics, Ophidia Medical Technologies, ATAI Life Sciences, Phaseform, Evotec, Sanity Group, Primmbiotech, , Vaccitech, Biolat, Pharmidea, Asla-Biotech, Genera, Anima Lab, Silvanols, OU TBD-Biodiscovery, Qvalitas Arstikeskus AS, Concise Systems OU, GPE Globalpharma OU, Belarusian National Biotechnology Corporation , Innothera , Olainfarm, Pharmaidea, Amgen Inc., Gilead Sciences, Celgene Corporation, Biogen Inc., Vertex Pharmaceuticals, Illumina, Inc., Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals , Hemostemix Inc., Resverlogix Corporation, Zenith Epigenetics Corp., Bayer, AMEGA Biotech, Pierre Fabre, Pfizer, Quantificare, Apsen Farmaceutica, BioMarin Pharmaceutical, DK Diagnostics, Biosonda Biotechnology, Laboratorios Legrand, Biomerics, Julphar Pharmaceuticals, Medpharma, Pharmax, Neopharma , City Breeze Technical Services, CinnaGen, BioSun Pharmed, AryoGen Pharmed, 4Clinics, 54gene, Amoun, Aspen Pharmacare, BBI Solutions, BioTech Africa, ClinArt MENA, Crux Pharmaceuticals, Genesis Pharmaceuticals, Massive Genomics, Mayne Pharma, Sanofi Genzyme, Teleflex Medical, The Micron Group.
Asia-Pacific was the largest region in the biotechnology services market in 2023. North America was the second largest region in the global biotechnology services market analysis. The regions covered in the biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biotechnology services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Key types of biotechnology services include prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, and research and development. Food biotechnology services cover various technologies applied in crops, livestock, forestry, fisheries, aquaculture, and agro-industry. These services are utilized for genetic improvement, conservation of genetic resources, disease diagnosis, vaccine development, and fermented food production. Applications of biotechnology services span the pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors, with usage by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS).
The biotechnology services market research report is one of a series of new reports that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The biotechnology services market size is expected to see strong growth in the next few years. It will grow to $163.12 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. Forecasted growth in biotechnology services is fueled by technological advancements, increased demand for agriculture-based services, and the rise of synthetic biology. Key trends include strategic collaborations, cloud-based data management, advanced sequencing and AI in drug research, digitalization in clinical trials, automation in diagnostics, and investments in synthetic biology for solutions in medicine, food supplies, chemicals, and renewable energy.
The increasing prevalence of diseases such as hepatitis B, diabetes, and cancer is fueling extensive research within the realm of biotechnology. This interdisciplinary field utilizes tools from biology and chemistry to scrutinize the genetic material of bacteria and viruses, effectively combating disease-causing agents. Notably, oncology research remains a cornerstone for biopharmaceutical companies, with advancements in stem cell therapy, monoclonal antibody treatments, and genome sequencing paving the way for significant medical applications. As per the Indian Economic Survey 2021, the Indian biotechnology sector is anticipated to burgeon to a valuation of US$ 150 billion by 2025. Consequently, the surge in disease prevalence and substantial investments in research and development are expected to be instrumental in propelling the growth of the biotechnology services market.
The escalating demand for clinical solutions catering to chronic disease treatments is set to be a significant driver for the expansion of the biotechnology services market. Chronic diseases encompass enduring medical conditions persisting for an extended duration, typically three months or more. Biotechnology services play a pivotal role in offering innovative clinical solutions for managing chronic diseases, including advanced therapies, precision medicine, and targeted treatments personalized to individual patients. These advancements significantly enhance the management and outcomes of chronic ailments. For instance, as per the World Health Organization (WHO) in September 2022, chronic diseases account for 74% of global deaths, amounting to 41 million fatalities annually. This includes 17.9 million deaths attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2.0 million to diabetes. Hence, the mounting demand for clinical solutions tailored to chronic disease treatment is a driving force behind the growth of the biotechnology services market.
Collaborations and partnerships between industry players are becoming increasingly prevalent in the biotech services sector. In January 2021, Novartis, a Swiss pharmaceutical company, entered into a collaboration with Alnylam, a US-based biopharmaceutical company. This partnership aimed to explore Alnylam's siRNA technology and develop targeted therapies to restore liver function. Under an exclusive three-year research collaboration, Alnylam would leverage Novartis' target-specific assays to develop and test potential siRNAs. Once a lead candidate is identified, Novartis would spearhead further development and clinical research efforts.
Key companies within the biotechnology services market are dedicated to pioneering innovative therapies, such as biomarker algorithms for the primary treatment of patients with non-small cell lung cancer (NSCLC). Biomarker algorithms encompass mathematical or computational models integrating data from multiple biological indicators to provide comprehensive assessments of specific medical conditions. For instance, in April 2023, Strata Oncology Inc., a US-based precision oncology company, introduced Strata Select - a groundbreaking molecular profiling test for advanced cancer patients. Noteworthy for being the first immunotherapy biomarker algorithm covered by Medicare across solid tumors, Strata Select empowers oncologists to make more informed treatment decisions, thereby enhancing patient outcomes.
In October 2021, Amgen, a US-based biopharmaceutical company, completed the acquisition of Teneobio for $2.5 billion. The acquisition included Teneobio's bispecific and multispecific antibody technologies, enhancing Amgen's antibody expertise and BiTE platform. This strategic move aims to advance the discovery of novel molecules for treating various diseases within Amgen's key therapeutic areas. TeneoBio, the acquired company, is a US-based biotechnology firm known for its expertise in producing human heavy chain antibodies.
Major companies operating in the biotechnology services market report are Parexel International Corporation, Thermo Fisher Scientific, Laboratory Corporation of America Holdings, IQVIA, ICON PLC, Charles River Laboratories, Syneos Health, Sartorius AG, Precision for Medicine Inc., Novartis, Eppendorf Asia Pacific Sdn. Bhd., Emmessar Biotech & Nutrition Ltd., Vcanbio Cell & Gene Engineering Corp., Ltd., Ke Rui Gene, Absea Biotechnology Ltd., CStone Pharm-B, Daiichi Sankyo, bitBiome, Taisho Pharmaceutical, AGC Biologics, Hamamatsu Pharma Research, Artios Pharma, AstraZeneca, Bio Products Laboratory (BPL), Cambridge Bioscience, Shire Pharmaceuticals Ltd., BTG Ltd., eXmoor Pharma, 4D Pharma PLC, Touchlight Genetics, Ophidia Medical Technologies, ATAI Life Sciences, Phaseform, Evotec, Sanity Group, Primmbiotech, , Vaccitech, Biolat, Pharmidea, Asla-Biotech, Genera, Anima Lab, Silvanols, OU TBD-Biodiscovery, Qvalitas Arstikeskus AS, Concise Systems OU, GPE Globalpharma OU, Belarusian National Biotechnology Corporation , Innothera , Olainfarm, Pharmaidea, Amgen Inc., Gilead Sciences, Celgene Corporation, Biogen Inc., Vertex Pharmaceuticals, Illumina, Inc., Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals , Hemostemix Inc., Resverlogix Corporation, Zenith Epigenetics Corp., Bayer, AMEGA Biotech, Pierre Fabre, Pfizer, Quantificare, Apsen Farmaceutica, BioMarin Pharmaceutical, DK Diagnostics, Biosonda Biotechnology, Laboratorios Legrand, Biomerics, Julphar Pharmaceuticals, Medpharma, Pharmax, Neopharma , City Breeze Technical Services, CinnaGen, BioSun Pharmed, AryoGen Pharmed, 4Clinics, 54gene, Amoun, Aspen Pharmacare, BBI Solutions, BioTech Africa, ClinArt MENA, Crux Pharmaceuticals, Genesis Pharmaceuticals, Massive Genomics, Mayne Pharma, Sanofi Genzyme, Teleflex Medical, The Micron Group.
Asia-Pacific was the largest region in the biotechnology services market in 2023. North America was the second largest region in the global biotechnology services market analysis. The regions covered in the biotechnology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biotechnology services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Key types of biotechnology services include prevention and disease control, public engagement activities, health education and research, food biotechnology services, donor recruitment, tissue collection, cell processing and isolation, and research and development. Food biotechnology services cover various technologies applied in crops, livestock, forestry, fisheries, aquaculture, and agro-industry. These services are utilized for genetic improvement, conservation of genetic resources, disease diagnosis, vaccine development, and fermented food production. Applications of biotechnology services span the pharmaceutical, biotechnological, academic, clinical trial, and healthcare sectors, with usage by Clinical Research Organizations (CROs), Contract Manufacturers Organizations (CMOs), and Contract Research and Manufacturing Services (CRAMS).
The biotechnology services market research report is one of a series of new reports that provides biotechnology services market statistics, including biotechnology services industry global market size, regional shares, competitors with a biotechnology services market share, detailed biotechnology services market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology services industry. This biotechnology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The biotechnology services market consists of revenue earned by entities that engage in conducting research and experimental development in biotechnology. Numerous global issues are helped by biotechnology, including infectious diseases, ageing societies, food security, energy security, and climate change, to name a few. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Biotechnology Services Market Characteristics3. Biotechnology Services Market Trends and Strategies32. Global Biotechnology Services Market Competitive Benchmarking33. Global Biotechnology Services Market Competitive Dashboard34. Key Mergers and Acquisitions in the Biotechnology Services Market
4. Biotechnology Services Market - Macro Economic Scenario
5. Global Biotechnology Services Market Size and Growth
6. Biotechnology Services Market Segmentation
7. Biotechnology Services Market Regional and Country Analysis
8. Asia-Pacific Biotechnology Services Market
9. China Biotechnology Services Market
10. India Biotechnology Services Market
11. Japan Biotechnology Services Market
12. Australia Biotechnology Services Market
13. Indonesia Biotechnology Services Market
14. South Korea Biotechnology Services Market
15. Western Europe Biotechnology Services Market
16. UK Biotechnology Services Market
17. Germany Biotechnology Services Market
18. France Biotechnology Services Market
19. Italy Biotechnology Services Market
20. Spain Biotechnology Services Market
21. Eastern Europe Biotechnology Services Market
22. Russia Biotechnology Services Market
23. North America Biotechnology Services Market
24. USA Biotechnology Services Market
25. Canada Biotechnology Services Market
26. South America Biotechnology Services Market
27. Brazil Biotechnology Services Market
28. Middle East Biotechnology Services Market
29. Africa Biotechnology Services Market
30. Biotechnology Services Market Competitive Landscape and Company Profiles
31. Biotechnology Services Market Other Major and Innovative Companies
35. Biotechnology Services Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Biotechnology Services Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on biotechnology services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biotechnology services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Service: Prevention and Disease Control; Public Engagement Activities; Health Education and Research; Food Biotechnology Services; Donor Recruitment; Tissue Collection; Cell Processing and Isolation; Research and Development
2) By Industry: Clinical Research Organizations (CROS); Contract Manufacturers Organizations (CMOS); and Contract Research and Manufacturing Services (CRAMS)
3) By Area Of Application: Pharmaceutical; Biotechnology; Academic; Clinical Trial; Healthcare Sectors; Others
Key Companies Mentioned: Parexel International Corporation; Thermo Fisher Scientific; Laboratory Corporation of America Holdings; IQVIA; ICON plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Parexel International Corporation
- Thermo Fisher Scientific
- Laboratory Corporation of America Holdings
- IQVIA
- ICON plc
- Charles River Laboratories
- Syneos Health
- Sartorius AG
- Precision for Medicine Inc.
- Novartis
- Eppendorf Asia Pacific Sdn. Bhd.
- Emmessar Biotech & Nutrition Ltd
- Vcanbio Cell & Gene Engineering Corp., Ltd
- Ke Rui Gene
- Absea Biotechnology Ltd
- CStone Pharm-B
- Daiichi Sankyo
- bitBiome
- Taisho Pharmaceutical
- AGC Biologics
- Hamamatsu Pharma Research
- Artios Pharma
- AstraZeneca
- Bio Products Laboratory (BPL)
- Cambridge Bioscience
- Shire Pharmaceuticals Ltd
- BTG Ltd
- eXmoor Pharma
- 4D Pharma PLC
- Touchlight Genetics
- Ophidia Medical Technologies
- ATAI Life Sciences
- Phaseform
- Evotec
- Sanity Group
- Primmbiotech
- Vaccitech
- Biolat
- Pharmidea
- Asla-Biotech
- Genera
- Anima Lab
- Silvanols
- OU TBD-Biodiscovery
- Qvalitas Arstikeskus AS
- Concise Systems OU
- GPE Globalpharma OU
- Belarusian National Biotechnology Corporation
- Innothera
- Olainfarm
- Pharmaidea
- Amgen Inc.
- Gilead Sciences
- Celgene Corporation
- Biogen Inc.
- Vertex Pharmaceuticals
- Illumina, Inc.
- Regeneron Pharmaceuticals Inc.
- Alexion Pharmaceuticals
- Hemostemix Inc.
- Resverlogix Corporation
- Zenith Epigenetics Corp.
- Bayer
- AMEGA Biotech
- Pierre Fabre
- Pfizer
- Quantificare
- Apsen Farmaceutica
- BioMarin Pharmaceutical
- DK Diagnostics
- Biosonda Biotechnology
- Laboratorios Legrand
- Biomerics
- Julphar Pharmaceuticals
- Medpharma
- Pharmax
- Neopharma
- City Breeze Technical Services
- CinnaGen
- BioSun Pharmed
- AryoGen Pharmed
- 4Clinics
- 54gene
- Amoun
- Aspen Pharmacare
- BBI Solutions
- BioTech Africa
- ClinArt MENA
- Crux Pharmaceuticals
- Genesis Pharmaceuticals
- Massive Genomics
- Mayne Pharma
- Sanofi Genzyme
- Teleflex Medical
- The Micron Group
Methodology
LOADING...